Psych Vivas · Psychopharmacology — fitness to drive
Psychotropics, sedation and driving — consultant viva
Fellowship viva covering residual hypnotic impairment, crash epidemiology, illness vs drug effects, counselling, and licence-class standards.
On this page & tools
Target exams
Opening (1–2 min)
Define fitness to drive as a clinical–functional judgment integrating illness severity, medication residual/psychomotor effects, substance co-use, and licence class — not a permanent ban on all psychotropics.[1][10]
Core probes and model points
1. Epidemiology cards
- Thomas: BZD use ≈ doubles MVC risk in case-control synthesis.[2]
- Hemmelgarn: long-half-life BZDs in the elderly raise crash risk.[3]
- Gustavsen: zopiclone/zolpidem/flunitrazepam/nitrazepam prescription-linked accident risk.[5]
- Dassanayake: meta-analytic synthesis across BZD, antidepressants, opioids.[9]
- Fournier: concurrent BZD + antidepressant in older drivers.[8]
2. SDLP and residual hypnotics
Name SDLP as on-road weaving metric. Residual morning impairment after bedtime BZD hypnotics and zopiclone is experimentally robust; zopiclone is often a positive control for residual impairment — kill the myth that Z-drugs are driving-safe by class label alone.[1][4][5]
3. Illness versus tablet
Wingen: long-term SSRI/SNRI-treated depressed patients can still show on-road impairment vs controls — residual illness matters.[6] Verster/Roth: methylphenidate can reduce highway attention lapses in ADHD — treat the disorder.[7] Brunnauer synthesis: patient driving performance often improves as treatment stabilises non-sedating regimens.[10]
4. Counselling script (say it aloud)
Warn at initiation; temporary restriction during titration/acute illness; never combine with alcohol; reassess when stable; document understanding and review date; commercial licences need higher standards and often occupational clearance.[1][10]
5. Regional principles
State Austroads / DVLA / local US frameworks as living standards; do not invent mandatory reporting statutes from memory — principles first, then check current guidance.[1][10]
Rapid-fire pearls
- Zopiclone ≠ automatic green light for morning commute.[4][5]
- Alcohol multiplies sedative risk every time.[1][9]
- Document or it did not happen medico-legally.[1]
- Commercial ≠ private standard.[1][10]
Examiner traps
- Claiming all antidepressants permanently unfit drivers.[6][10]
- Ignoring near-miss history while debating product class labels.[1]
- Clearing a truck driver on the same criteria as a private car user without occupational thought.[1][10]
References
- [1]Verster JC, Mets MA. Psychoactive medication and traffic safety Int J Environ Res Public Health, 2009.PMID 19440432
- [2]Thomas RE. Benzodiazepine use and motor vehicle accidents. Systematic review of reported association Can Fam Physician, 1998.PMID 9585853
- [3]Hemmelgarn B, Suissa S, Huang A, et al. Benzodiazepine use and the risk of motor vehicle crash in the elderly JAMA, 1997.PMID 9207334
- [4]Verster JC, Veldhuijzen DS, Volkerts ER. Residual effects of sleep medication on driving ability Sleep Med Rev, 2004.PMID 15233958
- [5]Gustavsen I, Bramness JG, Skurtveit S, et al. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam Sleep Med, 2008.PMID 18226959
- [6]Wingen M, Ramaekers JG, Schmitt JA. Driving impairment in depressed patients receiving long-term antidepressant treatment Psychopharmacology (Berl), 2006.PMID 16865389
- [7]Verster JC, Roth T. Methylphenidate significantly reduces lapses of attention during on-road highway driving in patients with ADHD J Psychopharmacol, 2014.PMID 24978156
- [8]Fournier JP, Wilchesky M, Patenaude V, et al. Concurrent Use of Benzodiazepines and Antidepressants and the Risk of Motor Vehicle Accident in Older Drivers: A Nested Case-Control Study CNS Drugs, 2015.PMID 26847674
- [9]Dassanayake T, Michie P, Carter G, et al. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence Drug Saf, 2011.PMID 21247221
- [10]Brunnauer A, Herpich F, Zwanzger P, et al. Driving Performance Under Treatment of Most Frequently Prescribed Drugs for Mental Disorders: A Systematic Review of Patient Studies Int J Neuropsychopharmacol, 2021.PMID 34038545